Biotechgate Global Database ›
News in the Life Sciences Industry | |
| Results 61 - 75 out of 75 displayed. | |
| « 1 2 3 4 | |
OliX Announces Clinical Candidate Nomination for the Treatment of Geographic Atrophy |
SUWON, South Korea, Jan. 18, 2019 /PRNewswire/ -- OLX10020, a cell-penetrating asymmetric siRNA ("cp-asiRNA") against a novel target (Undisclosed) for treatment of Geographic Atrophy ("GA"), proved effective in both Dry and Wet AMD animal models and to be submitted an IND application to the... Read more ›› |
| By: PR Newswire Association LLC. - 18 Jan 2019 |
| Related companies: OliX Pharmaceuticals, Inc |
Novo Nordisk A/S - Share repurchase programme |
| Read more ›› |
| By: Nasdaq / GlobenewsWire - 14 Jan 2019 |
Mundipharma to Bring World's First Gene Therapy for Osteoarthritis to Nine More Countries in APAC |
SINGAPORE, Jan. 14, 2019 /PRNewswire/ -- Mundipharma has acquired the exclusive rights for Invossa(®)-K in Singapore, Malaysia, the Philippines, Thailand, Vietnam, Indonesia, Myanmar, Australia and New Zealand from Kolon Life Sciences. Invossa(®)-K is a non-surgical treatment for osteoarthritis... Read more ›› |
| By: PR Newswire Association LLC. - 14 Jan 2019 |
B. Braun’s OnGuard® CSTD Qualifies as an Effective Barrier for Vapor Release Based on the NIOSH Draft Universal Protocol |
| Read more ›› |
| By: Nasdaq / GlobenewsWire - 08 Jan 2019 |
Novo Nordisk A/S - Share repurchase programme |
| Read more ›› |
| By: Nasdaq / GlobenewsWire - 07 Jan 2019 |
3SBio and Samsung Bioepis enter biosimilar collaboration agreement |
SHENYANG, China, Jan. 6, 2019 /PRNewswire/ -- Chinese leading Biopharmaceutical company 3SBio Inc. (01530.HK)("3SBio") announced today that it has entered into a collaboration agreement (the "Agreement") with Samsung Bioepis Co., Ltd. ("Samsung Bioepis") for the clinical... Read more ›› |
| By: PR Newswire Association LLC. - 07 Jan 2019 |
| Related companies: Samsung Bioepis Co., Ltd |
Novo Nordisk A/S: Share repurchase programme |
| Read more ›› |
| By: Nasdaq / GlobenewsWire - 21 Dec 2018 |
Mundipharma Applies to Market Remimazolam for General Anesthesia in Japan |
TOKYO, Dec. 21, 2018 /PRNewswire/ -- Mundipharma has submitted an application to the Japanese Pharmaceuticals and Medical Devices Agency to market Remimazolam for general anesthesia in Japan. Read more ›› |
| By: PR Newswire Association LLC. - 21 Dec 2018 |
S1 Biopharma Granted Patents for Lorexys(TM) in Europe and Asia for Treatment of Hypoactive Sexual Desire Disorder |
NEW YORK, Dec. 20, 2018 /PRNewswire/ -- S1 Biopharma, Inc. (S1) announced today that the European Patent Office has granted a European Patent for the Company's proprietary dual-mechanistic therapy Lorexys(TM) for hypoactive sexual desire disorder. A corresponding patent was previously... Read more ›› |
| By: PR Newswire Association LLC. - 20 Dec 2018 |
Bridge Biotherapeutics Signs US$40M License Agreement with Daewoong Pharmaceutical for Co-development of UC Drug Candidate |
SEONGNAM, South Korea, Dec. 18, 2018 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that the company signed a license agreement with Daewoong Pharmaceutical Co., Ltd. for development of BBT-401, the first anti-Pellino-1... Read more ›› |
| By: PR Newswire Association LLC. - 19 Dec 2018 |
Novo Nordisk A/S - Share repurchase programme |
| Read more ›› |
| By: Nasdaq / GlobenewsWire - 17 Dec 2018 |
Bridge Biotherapeutics Announces FDA Clearance of IND for its BBT-877, an Autotaxin Inhibitor for IPF |
SEONGNAM, South Korea, Dec. 16, 2018 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea and a tenant company of JLABS@TMC in Houston, Texas, announced that the Investigational New Drug (IND) application for BBT-877, a potent best-in-class... Read more ›› |
| By: PR Newswire Association LLC. - 17 Dec 2018 |
Novo Nordisk A/S - Share repurchase programme |
| Read more ›› |
| By: Nasdaq / GlobenewsWire - 10 Dec 2018 |
Kyowa Kirin Presents Additional Analyses of MAVORIC Trial |
TOKYO, Dec. 3, 2018 /PRNewswire/ -- Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin) announces that additional data from the MAVORIC trial (Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In CTCL) will be presented at the 60(th) Annual Meeting... Read more ›› |
| By: PR Newswire Association LLC. - 03 Dec 2018 |
| Related companies: Kyowa Hakko Kirin Korea Co., Ltd | Kyowa Hakko Kirin (China) Pharmaceutical Co., Ltd. | Kyowa Hakko Kirin Co., Ltd. |
Novo Nordisk A/S - Share repurchase programme |
| Read more ›› |
| By: Nasdaq / GlobenewsWire - 03 Dec 2018 |
| « 1 2 3 4 |
Partners
Upcoming Life Sciences Events
- May 2019
- New York: Inhalation & Respiratory Drug Delivery 2019
- June 2019
- Philadelphia, PA: Product and Company Valuation Course
- Philadelphia: RESI Philadelphia
